StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research note released on Friday morning. The firm issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
Genocea Biosciences has a 52-week low of $0.00 and a 52-week high of $0.00. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. The firm has a market cap of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61.
Genocea Biosciences Company Profile
Featured Stories
- Five stocks we like better than Genocea Biosciences
- How to Invest in Blue Chip Stocks
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- 3 Fintech Stocks With Good 2021 Prospects
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- How to Invest in Insurance Companies: A Guide
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.